USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE

• US 20180221443A1
• Filed: 04/05/2018
• Published: 08/09/2018
• Est. Priority Date: 04/30/2013
• Status: Active Grant

• Current Assignee: Korea University Research and Business Foundation
• Original Assignee: Korea University Research and Business Foundation
• Inventors: Ko, Je Sang, Kim, Jeong-Han
• Granted Patent: US 10,456,446 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: G01N 2333/47 Assays involving proteins of known structure or function as defined in the subgroups
• CPC Class Codes: G01N 33/502 for testing non-proliferative effects
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPARγ2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.

Claims

1. A screening method of a medicine for preventing or treating bone disease, comprising:

contacting a cell transformed with human small leucine-zipper proteins (sLZIP) and Peroxisome proliferator-activated receptor γ

2 (PPARγ

2) with a candidate material, wherein either the human sLZIP or PPARγ

2 is coupled to a detectable component; and

detecting an increase in formation of the complex of the human sLZIP and PPARγ

2 in the cell, whereby said candidate material is determined to be a material capable of preventing or treating bone disease.

2. The screening method of claim 1, wherein the cell is an animal cell.

3. The screening method of claim 2, wherein the detectable component is selected from the group consisting of a fluorescent protein, Glutathione S transferase (GST), Flag-tag, Myc-tag and HA-tag.

4. The screening method of claim 1, wherein detecting is carried out by a reaction using the detectable component, or the human sLZIP or PPARγ

2-specific antibody.

5. The screening method of claim 3, wherein detecting out by a reaction using the detectable component, or the human sLZIP or PPARγ

2-specific antibody.